EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Therapeutic modulation of dysbiosis along the gut–skin microbiome axis in dermatological disease

Ly T Nguyen, An T Nguyen, Claire Fason, Fyona Okundia, Muna Shakhashiro, Stephen K Tyring

Skin Health and Disease · 06.11.2026

DOI: 10.1093/skinhd/vzag168 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Skin Health and Disease, online erschienen am 06.11.2026. Verfasst von Ly T Nguyen und 5 weiteren Autor:innen. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The gut–skin axis represents a bidirectional network linking intestinal and cutaneous microbial communities with host immune signalling, metabolic activity and epithelial barrier function. Disruption of this system (dysbiosis) has been implicated in the pathogenesis of inflammatory dermatological conditions, including atopic dermatitis, psoriasis, acne vulgaris, hidradenitis suppurativa and chronic wounds. This review focuses on contemporary strategies aimed at normalizing dysbiosis rather than broadly suppressing inflammation or microbial communities. Recent studies (2022–26) suggest that immune-targeted therapies and microbiome-directed interventions exert secondary effects on microbial composition, diversity and function. Biologic agents and small-molecule inhibitors, including interleukin (IL)-4Rɑ, IL-13, IL-17/23 and Janus kinase pathway inhibitors, are associated with partial restoration of microbial diversity and reductions in pathogenic taxa, particularly Staphylococcus aureus, alongside clinical improvement. There are parallel advances in microbiome-targeted therapeutics that offer complementary or alternative approaches. Live biotherapeutic products, such as Roseomonas mucosa, Staphylococcus hominis A9, ammonia-oxidizing bacteria and noninflammatory Cutibacterium acnes phylotypes, demonstrate strain-specific pathogen suppression, epithelial function enhancement and immunomodulatory effects without promoting antimicrobial resistance. Postbiotic and metabolite-based therapies replicate commensal signalling through delivery of short-chain fatty acids, indole derivatives and aryl hydrocarbon receptor agonists, offering regulatory feasibility and stability advantages over live organisms. Bacteriophage and recombinant endolysin therapies provide precision eradication of pathogenic strains while preserving commensal ecosystems, with early translational and clinical data supporting safety and efficacy. Lastly, gut-targeted interventions, including dietary modification, oral probiotics, prebiotics and faecal microbiota transplantation, highlight the systemic contribution of intestinal microbial homeostasis to skin inflammation. These strategies collectively signal a paradigm shift toward ecological restoration and immune recalibration. This review synthesizes recent evidence on the therapeutic modulation of the gut–skin axis, integrating mechanistic insights with emerging clinical applications.

Zitieren

APA

Nguyen, L. T., Nguyen, A. T., Fason, C., Okundia, F., Shakhashiro, M., & Tyring, S. K. (2026). Therapeutic modulation of dysbiosis along the gut–skin microbiome axis in dermatological disease. Skin Health and Disease. https://doi.org/10.1093/skinhd/vzag168

Vancouver

Nguyen LT, Nguyen AT, Fason C, Okundia F, Shakhashiro M, Tyring SK. Therapeutic modulation of dysbiosis along the gut–skin microbiome axis in dermatological disease. Skin Health and Disease. 2026. doi:10.1093/skinhd/vzag168

BibTeX
@article{Nguyen2026,
  author = {Nguyen, Ly T and Nguyen, An T and Fason, Claire and Okundia, Fyona and Shakhashiro, Muna and Tyring, Stephen K},
  title = {Therapeutic modulation of dysbiosis along the gut–skin microbiome axis in dermatological disease},
  journal = {Skin Health and Disease},
  year = {2026},
  doi = {10.1093/skinhd/vzag168}
}
Kostenlos starten →